In this study, we initially developed OHSV2-DSTEFAP5/CD3 and designed an innovative high-order combination by incorporating OHSV2-DSTEFAP5/CD3, GPC3-targeting CAR-T cells, and immunotoxins (27) in a mouse HCC model. Here, GPC3 is linked to hepatocellular carcinoma.